This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_SECONDARY_WITHOUT_SITESPEC_EXALLC for full statistics.
Malignant neoplasm, without specification of site
C3_SECONDARY_WITHOUT_SITESPEC
cancer: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
1178 |
4. Check minimum number of eventsNone |
1178 |
5. Include endpointsNone |
1178 |
6. Filter based on genotype QC (FinnGen only) |
1178 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm, without specification of site
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm, without specification of site, excluding all cancers (controls excluding all cancers)
- Secondary uncertain malignant neoplasm
- Secondary uncertain malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1178 | 440 | 738 |
| Unadjusted period prevalence (%) | 0.26 | 0.15 | 0.33 |
| Median age at first event (years) | 71.84 | 70.75 | 72.48 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1122
- Matched controls
- 11218
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8000/3-C80.9
ICD-O-3
Neoplasm, malignant of unknown primary site
+∞
314.9
287
*
C80
ICD-10 Finland
Malignant neoplasm, without specification of site
595.0
247.8
237
5
8140/3-C80.9
ICD-O-3
Adenocarcinoma, NOS, of unknown primary site
+∞
205.7
191
*
130
Kela drug reimbursment
Malignant tumour
8.7
148.8
362
582
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
22.5
124.0
184
97
C80.0
ICD-10 Finland
Malignant neoplasm, primary site unknown, so stated
+∞
122.2
115
*
8070/3-C80.9
ICD-O-3
Squamous cell carcinoma, NOS, of unknown primary site
+∞
114.6
108
*
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
73.7
94.4
107
16
8010/3-C80.9
ICD-O-3
Carcinoma, NOS, of unknown primary site
+∞
88.7
84
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.2
86.0
409
1347
C80.99
ICD-10 Finland
Malignant tumor without specified localization or histology
153.1
81.2
85
6
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
50.6
77.3
93
20
C80.92
ICD-10 Finland
Malignant tumor without specified localization adenocarcinoma
107.6
73.9
80
8
N02AA05
ATC
oxycodone; systemic
3.9
72.4
369
1257
9680/3-C80.9
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of unknown primary site
+∞
71.6
68
*
Z51.5
ICD-10 Finland
Palliative care
5.6
64.6
208
441
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
8.8
58.5
131
166
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.0
57.0
126
156
JN4BD
NOMESCO Finland
Extensive body CT
4.1
57.0
253
742
H02AB02
ATC
dexamethasone; systemic
4.6
56.6
220
567
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
76.2
51.5
58
8
C80.9
ICD-10 Finland
Malignant neoplasm, primary site unspecified
509.5
49.8
49
*
A04AA02
ATC
granisetron; systemic, transdermal
6.0
46.6
137
255
8246/3-C80.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of unknown primary site
+∞
44.0
42
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
11.6
43.2
82
76
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
14.2
41.2
71
53
WF049
NOMESCO Finland
Radiotherapy of metastasis
6.9
40.9
107
170
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
12.2
37.0
68
59
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.1
35.5
117
248
8720/3-C80.9
ICD-O-3
Malignant melanoma, NOS, of unknown primary site
+∞
34.6
33
*
A04AA01
ATC
ondansetron; systemic, rectal
4.5
32.9
123
297
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
21.7
31.5
46
22
L03AA13
ATC
pegfilgrastim; parenteral
6.3
29.2
80
135
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
67.9
29.0
33
5
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
18.3
28.5
44
25
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
9.5
28.4
59
65
EMB10
NOMESCO Finland
Tonsillectomy
7.6
27.6
66
92
C80.98
ICD-10 Finland
Malignant tumor without specified localization other specified histology
+∞
27.2
26
*
1990X
ICD-9 Finland
Malignant neoplasm without specification of site, Disseminated
77.1
26.9
30
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
13.2
26.8
47
37
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
23.1
26.7
38
17
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
3.7
26.5
122
356
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
6.0
25.8
73
129
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
7.2
24.8
61
89
8480/3-C80.9
ICD-O-3
Mucinous adenocarcinoma of unknown primary site
+∞
24.0
23
*
JN4AD
NOMESCO Finland
Body CT examination
3.2
24.0
137
471
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
5.0
23.9
79
168
R18
ICD-10 Finland
Ascites
7.9
23.0
53
70
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
6.2
22.3
61
103
8240/3-C80.9
ICD-O-3
Neuroendocrine tumor, NOS, of unknown primary site
+∞
21.9
21
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.0
21.9
341
1988
A98
ICPC
Health maint/preventive medicine
0.5
21.4
605
7686
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
28.7
21.0
28
10
JN4CD
NOMESCO Finland
Very extensive body CT
4.0
20.3
83
218
8041/3-C80.9
ICD-O-3
Small cell carcinoma, NOS, of unknown primary site
+∞
19.8
19
*
8249/3-C80.9
ICD-O-3
Neuroendocrine tumor, grade 2 of unknown primary site
+∞
19.8
19
*
H01CB02
ATC
octreotide; parenteral
25.1
19.6
27
11
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.9
19.5
37
35
L03AA02
ATC
filgrastim; parenteral
5.6
19.1
56
104
WW500
NOMESCO Finland
Blood transfusion
4.0
19.1
78
205
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
10.9
19.0
36
34
XW4AT
NOMESCO Finland
Biopsy of other inner organ with ultrasound guidance
35.0
18.9
24
7
WF003
NOMESCO Finland
Adjuvant radiotherapy
4.5
18.9
68
158
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
3.3
18.3
97
316
C80.91
ICD-10 Finland
Malignant tumor without specified localization epidermoid carcinoma
53.4
18.0
21
*
UJC01
NOMESCO Finland
Scopy of lower throat
9.1
17.7
37
42
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
8.4
16.6
36
44
C43.99
ICD-10 Finland
Unspecified localization of malignant melanoma of the skin other or unspecified histology
20.4
16.5
24
12
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
7.3
16.4
39
55
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
12.4
16.4
29
24
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
16.4
173
840
JDB10
NOMESCO Finland
Percutaneous gastrostomy
7.0
16.3
40
59
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.3
16.3
83
263
WF002
NOMESCO Finland
Radical radiotherapy
3.3
16.2
83
264
C78.2
ICD-10 Finland
Secondary malignant neoplasm of pleura
24.9
16.0
22
9
PJA10
NOMESCO Finland
Exploration of lymph nodes
9.2
16.0
33
37
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.8
15.8
350
2264
8020/3-C80.9
ICD-O-3
Carcinoma, undifferentiated, NOS, of unknown primary site
+∞
15.7
15
*
UJC20
NOMESCO Finland
Extensive endoscopy to identify diagnosed or suspected primary malignant neoplasm of head or neck
+∞
15.7
15
*
XW000
NOMESCO Finland
Bone marrow biopsy
3.3
15.0
76
240
XX3DW
NOMESCO Finland
Time consuming IT work
2.5
14.9
125
541
C83.3
ICD-10 Finland
Diffuse large B-cell lymphoma
14.4
14.6
24
17
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
11.0
14.5
27
25
PJD51
NOMESCO Finland
Block dissection of cervical lymph nodes
36.5
14.5
18
5
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
6.0
14.3
39
67
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
43.1
14.1
17
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
6.8
14.1
35
53
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
17.8
13.9
21
12
C76.8
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Overlapping lesion of other and ill-defined sites
54.0
13.8
16
*
C83.39
ICD-10 Finland
Diffuse non-Hodgkin's large cell lymphoma UNS
24.1
13.8
19
8
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
20.3
13.8
20
10
WZC30
NOMESCO Finland
Teaching
2.2
13.7
142
683
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
5.4
13.6
40
76
UDQ22
NOMESCO Finland
Microlaryngoscopy
8.9
13.5
28
32
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
16.4
13.5
21
13
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
7.1
12.9
31
45
D48.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Neoplasm of uncertain or unknown behaviour, unspecified
5.4
12.8
38
73
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
15.6
12.6
20
13
9670/3-C80.9
ICD-O-3
Malignant lymphoma, small B lymphocytic, NOS, of unknown primary site
+∞
12.5
12
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.2
12.3
130
628
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
6.7
12.1
30
46
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
18.3
12.1
18
10
ZX120
NOMESCO Finland
Intravenous
2.2
11.8
120
571
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
9.8
11.8
23
24
J01MA12
ATC
levofloxacin; systemic
1.8
11.6
236
1466
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.9
11.6
171
950
D77
ICPC
Malignant digestive neopl other/NOS
13.8
11.5
19
14
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.9
11.4
68
242
C48.89
ICD-10 Finland
Overall malignant tumor of the peritoneum and retroperitoneum other or unspecified tumor
35.4
11.3
14
*
E34.0
ICD-10 Finland
Carcinoid syndrome
17.2
11.2
17
10
B01AB10
ATC
tinzaparin; parenteral
2.6
11.2
84
343
R4190
NOMESCO Finland
Nutritional therapy
4.4
10.9
39
92
WF004
NOMESCO Finland
Palliative radiotherapy
4.1
10.7
41
104
L01AX03
ATC
temozolomide; systemic
13.0
10.7
18
14
C48.00
ICD-10 Finland
Malignant tumor of the retroperitoneal space without histology
60.6
10.6
12
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
6.3
10.5
27
44
9591/3-C80.9
ICD-O-3
Malignant lymphoma, non-Hodgkin, NOS, of unknown primary site
+∞
10.4
10
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
4.8
10.3
33
70
H01CB03
ATC
lanreotide; parenteral
19.0
10.3
15
8
C79.3
ICD-10 Finland
Secondary malignant neoplasm of brain and cerebral meninges
23.6
10.3
14
6
WX408
NOMESCO Finland
General anesthesy, balanced
1.7
10.2
252
1653
1XC02
NOMESCO Finland
NA
8.0
10.1
22
28
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
8.5
10.1
21
25
C83.1
ICD-10 Finland
Mantle cell lymphoma
14.7
10.0
16
11
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
3.0
9.9
56
192
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.5
9.6
63
1278
ZX070
NOMESCO Finland
Intensity modified radiotherapy
4.1
9.4
35
87
9673/3-C80.9
ICD-O-3
Mantle cell lymphoma of unknown primary site
+∞
9.4
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
4.8
9.4
30
64
C22.1
ICD-10 Finland
Malignant neoplasm: Intrahepatic bile duct carcinoma
9.6
9.3
18
19
A79
ICPC
Malignancy NOS
4.7
8.9
29
63
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
10.8
8.8
16
15
JAH00
NOMESCO Finland
Laparotomy
3.2
8.8
45
146
ZX090
NOMESCO Finland
Other technic of radiotherapy
3.2
8.7
43
136
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
16.4
8.6
13
8
C76.0
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Head, face and neck
90.7
8.4
9
*
C76.7
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Other ill-defined sites
90.7
8.4
9
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
0.6
8.4
128
2031
9590/3-C80.9
ICD-O-3
Malignant lymphoma, NOS, of unknown primary site
+∞
8.3
8
*
9699/3-C80.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of unknown primary site
+∞
8.3
8
*
J94.8
ICD-10 Finland
Other specified pleural conditions
3.5
8.2
37
109
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
2.3
8.2
74
333
A04AD12
ATC
aprepitant; systemic
4.9
8.1
25
52
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
9.0
8.0
16
18
JN4ED
NOMESCO Finland
Body CT examination with specail preparation
22.2
8.0
11
5
JAL20
NOMESCO Finland
Excision or destruction of lesion of peritoneum
22.2
8.0
11
5
C43.9
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of skin, unspecified
22.2
8.0
11
5
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
7.8
7.9
17
22
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
5.2
7.9
23
45
UJC02
NOMESCO Finland
Rigid oesophagoscopy
6.2
7.9
20
33
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
5.8
7.8
21
37
JAH01
NOMESCO Finland
Laparoscopy
3.1
7.8
41
136
C77.3
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Axillary and upper limb lymph nodes
9.5
7.8
15
16
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
4.4
7.7
26
60
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.5
7.7
57
1110
UGC12
NOMESCO Finland
Flexible bronchoscopy
1.9
7.6
105
571
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
10.1
7.5
14
14
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
1.8
7.5
135
801
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
4.9
7.5
23
48
C48.09
ICD-10 Finland
Malignant tumor of the retroperitoneal space other or unspecified tumor
80.6
7.4
8
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.0
7.3
97
515
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
2.3
7.3
64
286
A07AA02
ATC
nystatin; oral
2.1
7.3
76
367
JAL30
NOMESCO Finland
Omentectomy
6.9
7.3
17
25
9702/3-C80.9
ICD-O-3
Mature T-cell lymphoma, NOS, of unknown primary site
+∞
7.3
7
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
6.3
7.3
18
29
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
4.7
7.2
23
50
H29
ICPC
Ear symptom/complaint other
0.4
7.1
22
592
Z87.1
ICD-10 Finland
Personal history of diseases of the digestive system
0.6
7.1
170
2448
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
3.0
7.1
38
129
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
6.1
7.1
18
30
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
8.8
7.1
14
16
SAA01
NOMESCO Finland
Simple examination of mouth
0.7
7.0
343
4332
C10AA05
ATC
atorvastatin; oral
0.7
7.0
248
3311
C10AA07
ATC
rosuvastatin; oral
0.6
6.9
103
1656
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
5.9
6.9
18
31
D39.10
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary without histology
4.7
6.9
22
48
L01BC06
ATC
capecitabine; oral
2.7
6.8
44
166
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
3.6
6.8
29
83
N02AX02
ATC
tramadol; systemic, rectal
1.4
6.8
437
3497
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
3.7
6.8
28
78
C26.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of digestive system
40.3
6.8
8
*
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
16.8
6.7
10
6
JN6AD
NOMESCO Finland
CT of torso and neck
4.9
6.7
20
41
C96.9
ICD-10 Finland
Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified
22.7
6.7
9
*
C79.31
ICD-10 Finland
Secondary malignant tumor of the cerebellum
22.7
6.7
9
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
5.2
6.6
19
37
C83.00
ICD-10 Finland
Lymphocytic lymphoma
7.9
6.6
14
18
K85
ICPC
Elevated blood pressure
0.5
6.6
52
995
R50.9
ICD-10 Finland
Fever, unspecified
1.7
6.5
150
958
1552X
ICD-9 Finland
Malignant neoplasm of liver and intrahepatic bile ducts, Liver, not specified as primary or secondary[NEOPLASMA MALIGNUMHEPATIS, NON DEFINITUM PRIM/SEC]
70.2
6.4
7
*
C78.1
ICD-10 Finland
Secondary malignant neoplasm of mediastinum
70.2
6.4
7
*
C18.19
ICD-10 Finland
Malignant tumor in appendix other or unspecified histology
14.4
6.4
10
7
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
11.1
6.3
11
10
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
18.1
6.3
9
5
C79.0
ICD-10 Finland
Secondary malignant neoplasm of kidney and renal pelvis
26.8
6.2
8
*
M04AA01
ATC
allopurinol; systemic
1.6
6.2
188
1285
I25.1
ICD-10 Finland
Atherosclerotic heart disease
0.7
6.2
200
2728
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.8
6.1
36
130
C82.9
ICD-10 Finland
Follicular lymphoma, unspecified
7.7
6.1
13
17
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
2.3
6.1
52
229
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
8.6
6.1
12
14
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
0.5
6.0
58
1047
ZX112
NOMESCO Finland
Subcutaneous
3.3
6.0
28
87
GDA98
NOMESCO Finland
Other bronchoscopic incision, excision of lesion or repair of lung
5.6
6.0
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
303
983
3.80
79.50
2.8
3.9
51.6
23.8
ug/l
1.04
257
827
145
357
4.49
54.51
2.2
3.2
2418.1
8608.5
u/ml
0.39
114
301
90
199
4.81
38.39
2.4
3.3
1517.7
1832.3
u/ml
0.08
81
189
500
7159
0.48
33.34
6.0
6.4
41.8
41.2
mmol/mol
0.72
422
6450
83
197
4.46
32.39
1.2
1.2
—
—
—
0
0
42
53
8.18
31.26
1.1
1.2
—
—
—
0
0
102
290
3.76
31.15
4.8
3.1
245.0
62.7
u/ml
2.05
102
278
240
1112
2.45
30.66
5.8
3.4
317.1
242.5
u/l
1.93
226
1039
542
7453
0.49
30.32
4.1
5.2
2.6
2.5
mmol/l
0.21
454
6629
520
7220
0.50
29.43
3.8
4.6
4.5
4.4
mmol/l
0.37
453
6477
518
7140
0.51
27.63
3.8
4.5
1.4
1.4
mmol/l
0.78
445
6334
554
7409
0.52
25.69
4.8
4.9
6.2
6.1
mmol/l
0.33
479
6510
513
6900
0.55
22.41
3.6
4.1
1.3
1.3
mmol/l
0.79
433
6067
683
8351
0.57
19.30
38.6
25.8
123.5
131.6
g/l
29.72
667
8137
683
8349
0.57
19.24
38.3
25.6
4.1
4.4
e12/l
20.66
655
8027
683
8348
0.57
19.21
38.3
25.7
253.3
237.9
e9/l
4.13
660
8062
241
1385
1.93
16.91
4.6
2.9
0.8
0.8
mmol/l
4.81
219
1275
79
1893
0.38
16.68
1.7
1.6
1.6
1.3
mmol/l
1.93
67
1553
673
8154
0.59
16.56
29.5
21.4
4.0
4.0
mmol/l
1.24
655
7871
673
8144
0.59
16.32
29.5
21.2
138.4
139.5
mmol/l
15.84
655
7870
560
7079
0.60
16.06
26.2
16.9
75.4
71.2
ml/min/173m2
4.59
493
5889
667
8033
0.61
15.01
17.2
10.6
28.8
24.6
u/l
3.27
640
7636
584
4472
1.61
14.07
11.6
5.7
17.5
12.2
umol/l
2.37
564
4205
31
65
4.87
14.07
1.6
3.5
42.4
68.3
u/ml
0.47
31
65
552
6898
0.62
13.91
5.1
4.6
7.4
2.2
mu/l
0.50
486
6092
151
817
1.97
12.43
2.1
2.0
0.2
0.2
g/l
1.63
134
754
244
3621
0.59
12.02
2.6
2.4
—
—
—
0
0
54
192
2.90
11.51
2.3
2.3
38.5
34.0
umol/l
0.50
38
146
66
266
2.57
11.07
1.7
1.6
—
—
—
0
0
250
3589
0.61
10.36
4.2
5.4
4.0
5.2
ug/l
0.30
214
3146
18
31
5.88
10.08
1.2
1.7
24376.7
50163.2
e6/l
0.22
12
22
191
2865
0.60
9.29
3.9
4.7
21.5
22.1
%
0.23
101
1475
56
230
2.51
9.07
1.6
1.4
—
—
—
0
0
156
942
1.76
9.00
4.2
2.5
16.0
9.4
umol/l
0.81
138
817
672
7748
0.69
8.58
28.2
17.8
38.4
28.2
mg/l
8.74
621
6415
74
354
2.16
8.48
2.6
2.9
—
—
—
0
0
151
2347
0.59
8.32
1.6
1.6
19.6
20.2
nmol/l
0.17
135
1972
560
6646
0.70
8.22
27.2
19.1
36.3
38.2
%
3.51
345
4063
17
35
4.91
7.90
2.0
2.1
—
—
—
0
0
38
138
2.81
7.86
1.4
1.3
63512.2
83481.8
e6/l
0.16
27
81
17
37
4.65
7.42
1.8
1.9
12.7
18.7
%
—
6
15
175
2556
0.63
7.30
2.8
3.1
7.3
7.1
mmol/l
0.19
131
2059
186
2676
0.64
7.24
3.5
3.9
6.7
9.4
mg/mmol
0.68
117
1710
293
3846
0.68
7.24
1.9
2.1
92.0
91.5
pmol/l
0.05
153
1981
16
35
4.62
6.94
2.4
1.9
—
—
—
0
0
16
35
4.62
6.94
2.4
1.9
—
—
—
0
0
136
849
1.68
6.93
3.0
2.5
64.7
66.0
g/l
0.84
119
748
516
6109
0.72
6.80
31.8
21.2
14.6
14.0
%
11.45
506
5941
39
156
2.55
6.73
1.4
1.4
1478.5
1386.3
e6/l
0.07
32
109
16
36
4.49
6.72
2.6
1.9
—
—
—
0
0
478
3910
1.37
6.41
7.0
4.6
32.0
34.3
g/l
11.19
446
3592
134
2017
0.62
6.27
2.6
3.3
0.6
0.8
ug/l
3.67
99
1423
342
2654
1.41
6.27
3.5
2.4
52.6
56.7
u/l
1.05
319
2435
15
35
4.33
6.03
1.5
1.3
82.2
26.8
ug/l
—
9
16
28
100
2.84
6.02
1.4
1.2
20.2
9.7
u/l
1.84
22
77
25
84
3.02
5.98
1.2
1.2
—
—
—
0
0
473
5608
0.74
5.92
4.2
3.7
15.1
15.1
pmol/l
0.12
410
4916
82
472
1.79
5.59
2.1
1.8
1.7
2.2
ug/l
0.22
72
395
17
47
3.66
5.49
4.6
3.2
—
—
—
0
0
115
732
1.63
5.45
3.3
2.4
31.8
31.3
u/l
0.06
99
618
13
30
4.37
5.30
1.0
1.1
16.8
15.0
g/l
0.33
13
19
531
4505
1.33
5.28
15.7
8.0
4.5
4.4
e9/l
0.48
480
3911
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
66
368
1.84
5.01
1.9
2.4
0.3
0.4
u/ml
0.83
37
209
252
3221
0.72
4.89
2.2
2.2
75.1
78.6
nmol/l
1.16
222
2766
38
178
2.17
4.70
1.7
1.4
—
—
—
0
0
30
127
2.40
4.68
1.2
1.1
—
—
—
0
0
35
161
2.21
4.53
2.0
1.7
—
—
—
0
0
16
49
3.30
4.48
2.4
1.7
—
—
—
0
0
16
49
3.30
4.48
2.4
1.7
—
—
—
0
0
16
49
3.30
4.48
2.4
1.7
—
—
—
0
0
16
49
3.30
4.48
2.4
1.7
—
—
—
0
0
44
223
2.01
4.45
1.9
1.6
—
—
—
0
0
45
232
1.98
4.35
1.4
1.4
—
—
—
0
0
45
232
1.98
4.35
1.4
1.4
—
—
—
0
0
8
9
8.94
4.28
1.0
2.6
—
—
—
0
0
298
2385
1.33
4.27
4.8
3.0
80.5
34.9
u/l
0.99
282
2266
509
5818
0.78
4.23
4.7
4.0
23.4
15.1
mm/h
10.09
447
5243
61
1006
0.58
4.10
1.2
1.2
39.4
13.5
u/ml
0.69
22
355
41
210
1.99
4.05
1.9
1.6
—
—
—
0
0
365
3029
1.30
4.00
6.6
3.3
2.4
2.3
mmol/l
0.25
332
2575
155
2082
0.71
3.96
1.5
1.8
449.9
12263467.8
pmol/l
1.32
111
1688
32
151
2.15
3.93
4.7
3.5
2.7
1.7
%
0.50
25
119
11
29
3.82
3.81
1.5
1.3
—
—
—
0
0
27
122
2.24
3.69
1.5
1.5
—
—
—
0
0
13
40
3.28
3.63
4.2
2.3
496.8
674.9
e6/l
—
8
17
24
104
2.33
3.61
1.5
1.6
—
—
—
0
0
15
51
2.97
3.58
2.3
2.0
—
—
—
0
0
21
86
2.47
3.56
2.2
1.8
—
—
—
0
0
73
1111
0.63
3.53
11.7
9.2
—
—
—
0
0
9
17
5.33
3.51
5.1
2.0
—
—
—
0
0
20
81
2.49
3.47
2.3
1.8
—
—
—
0
0
256
2064
1.31
3.42
2.7
2.4
—
—
—
0
0
31
154
2.04
3.37
1.5
1.4
—
—
—
0
0
9
18
5.03
3.37
1.9
1.6
—
—
—
0
0
333
3928
0.79
3.34
4.0
4.1
0.0
0.0
estimate
0.00
76
749
272
3279
0.78
3.25
2.7
2.7
304.5
152.9
ug/l
3.45
240
2934
340
3981
0.79
3.16
4.1
4.2
0.0
0.0
estimate
0.00
74
737
18
74
2.45
3.05
1.4
1.7
—
—
—
0
0
336
3921
0.80
2.99
5.4
5.6
0.0
0.0
estimate
0.00
75
739
13
46
2.85
2.92
1.5
1.6
—
—
—
0
0
15
58
2.61
2.88
1.4
1.5
—
—
—
0
0
29
150
1.96
2.86
3.6
3.7
61.5
59.9
%
0.20
29
150
13
47
2.79
2.82
4.2
2.3
—
—
—
0
0
13
47
2.79
2.82
1.5
1.6
—
—
—
0
0
5
6
8.36
2.75
1.0
1.0
—
—
—
0
0
32
178
1.82
2.57
2.3
2.2
224.8
201.8
%
0.74
32
170
24
121
2.00
2.57
1.5
1.5
—
—
—
0
0
15
328
0.45
2.55
1.9
1.8
—
—
—
0
0
27
143
1.91
2.52
3.0
3.1
4.9
4.5
e9/l
0.31
27
143
8
21
3.83
2.46
1.0
1.0
—
—
—
0
0
24
125
1.94
2.36
1.5
1.6
—
—
—
0
0
174
2135
0.78
2.33
1.9
1.8
1216.2
1201.4
nmol/l
0.07
118
1580
20
99
2.04
2.27
1.1
1.2
299.5
313.0
u/ml
0.07
15
54
95
706
1.38
2.23
1.6
1.7
—
—
—
0
0
24
426
0.55
2.21
3.5
4.5
1.6
1.5
%
0.11
24
398
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
6
14
4.30
2.15
1.5
3.0
166.0
127.0
%
—
6
14
152
1219
1.28
2.12
4.8
4.9
1.0
1.0
mmol/l
0.08
135
1110
111
853
1.33
2.11
7.4
6.2
10.8
11.8
mmol/l
0.55
104
802
277
3192
0.83
2.05
3.5
3.2
2469.0
2188.8
ng/l
0.38
238
2759
6
15
4.02
2.04
2.5
1.3
—
—
—
0
0
20
104
1.94
2.01
1.1
1.2
—
—
—
0
0
50
337
1.51
1.99
2.8
3.3
77.6
76.5
mg/l
0.01
38
270
50
338
1.50
1.97
2.8
3.3
32.1
84.1
mg/l
0.79
38
275
17
84
2.04
1.96
2.4
1.6
—
—
—
0
0
17
84
2.04
1.96
2.4
1.6
—
—
—
0
0
17
84
2.04
1.96
2.4
1.6
—
—
—
0
0
5
11
4.56
1.94
1.0
1.1
—
—
—
0
0
24
135
1.79
1.92
1.5
1.4
—
—
—
0
0
49
334
1.49
1.87
1.3
1.2
—
—
—
0
0
43
286
1.52
1.84
1.3
1.8
34.1
37.4
u/l
0.50
35
242
451
4094
1.16
1.77
6.5
5.6
1.2
1.2
mmol/l
0.60
416
3654
43
621
0.68
1.71
3.0
3.0
119.2
125.3
g/l
1.25
43
607
78
1018
0.75
1.69
4.2
4.7
35.7
32.8
%
1.04
50
647
15
77
1.96
1.59
1.7
1.6
—
—
—
0
0
109
1349
0.79
1.59
1.2
1.2
1.5
1.4
u/ml
0.07
24
327
54
391
1.40
1.54
3.0
2.4
3.5
3.8
g/l
0.63
33
269
146
1214
1.23
1.53
3.1
2.2
1.9
1.8
%
0.67
123
1063
54
392
1.40
1.52
3.0
2.4
—
—
—
0
0
273
3075
0.85
1.51
4.4
4.5
—
—
—
0
0
54
393
1.39
1.51
3.0
2.4
8.0
7.5
g/l
0.77
33
280
11
51
2.17
1.51
1.0
1.0
—
—
—
0
0
212
1833
1.19
1.50
6.3
3.2
2.5
2.5
mmol/l
3.75
187
1590
23
141
1.64
1.42
1.0
1.3
—
—
—
0
0
236
2676
0.85
1.41
2.6
2.1
232.3
249.1
u/l
0.10
221
2482
50
365
1.39
1.39
2.2
2.5
10.3
10.7
g/l
0.15
38
300
85
1061
0.79
1.35
1.2
1.2
45.8
39.9
iu/ml
0.10
29
341
6
24
2.51
1.30
1.5
1.2
—
—
—
0
0
8
35
2.29
1.27
2.0
1.4
47.8
35.6
u/l
—
8
28
49
363
1.37
1.26
3.1
2.5
3.5
3.2
g/l
0.49
34
275
155
1800
0.84
1.24
4.9
4.6
1.0
1.0
kg/l
0.42
30
265
63
488
1.31
1.22
1.9
1.7
1.8
1.6
g/l
0.73
47
420
5
19
2.64
1.21
1.0
1.4
—
—
—
0
0
342
3729
0.88
1.16
4.6
4.3
45.4
58.3
ng/l
0.48
280
2887
5
20
2.51
1.15
1.4
1.6
1.2
1.2
mmol/l
—
5
20
48
629
0.75
1.14
1.4
1.3
—
—
—
0
0
22
143
1.55
1.12
1.2
1.2
4.0
3.9
mmol/l
0.07
22
134
536
5682
0.90
1.11
5.1
5.2
2229.3
2649.4
e6/l
0.07
20
109
197
2222
0.86
1.10
4.4
4.4
0.0
0.0
estimate
0.00
65
703
160
1832
0.85
1.09
4.4
4.2
195.5
309.1
ng/l
0.45
129
1591
17
105
1.63
1.06
2.1
2.7
—
—
—
0
0
36
486
0.73
1.05
3.7
3.8
46.2
46.8
%
0.05
36
480
24
162
1.49
1.04
1.2
1.2
638.7
515.2
mg/l
0.29
24
152
411
3826
1.11
1.00
5.1
4.3
—
—
—
0
0
36
266
1.36
0.99
2.6
2.6
0.0
0.0
g/l
0.00
28
240
7
36
1.95
0.97
1.1
1.3
—
—
—
0
0
14
222
0.63
0.95
1.4
1.7
—
—
—
0
0
116
998
1.18
0.92
4.5
3.9
—
—
—
0
0
36
271
1.34
0.90
2.6
2.6
0.0
0.0
g/l
0.00
28
241
10
56
1.79
0.88
1.3
1.4
—
—
—
0
0
90
761
1.20
0.87
6.0
3.7
1.2
1.2
mmol/l
0.32
82
656
6
31
1.94
0.84
1.2
2.0
4763.3
1242.7
u/ml
—
6
31
8
45
1.78
0.84
1.1
1.2
—
—
—
0
0
8
47
1.71
0.80
1.1
1.0
—
—
—
0
0
474
4490
1.09
0.79
7.6
6.4
1.2
1.2
mmol/l
1.32
376
3723
6
34
1.77
0.76
1.0
1.1
—
—
—
0
0
13
83
1.57
0.75
1.5
1.3
0.6
0.6
nmol/l
0.02
13
76
5
24
2.09
0.74
1.2
1.1
—
—
—
0
0
19
265
0.71
0.73
1.0
1.0
—
—
—
0
0
39
309
1.27
0.71
2.5
2.4
35.6
36.5
g/l
0.32
31
254
11
69
1.60
0.68
1.5
1.3
—
—
—
0
0
53
633
0.83
0.65
1.9
1.7
—
—
—
0
0
10
154
0.65
0.64
1.7
1.8
—
—
—
0
0
36
287
1.26
0.64
2.6
2.5
0.0
0.0
g/l
0.95
28
256
50
417
1.21
0.61
2.7
1.9
—
—
—
0
0
10
151
0.66
0.60
1.4
1.8
31.3
42.9
nmol/l
—
10
143
8
55
1.46
0.56
1.3
1.1
—
—
—
0
0
63
727
0.86
0.54
1.2
1.3
—
—
—
0
0
16
117
1.37
0.52
9.2
5.6
10.8
12.6
mg/l
1.41
16
108
491
5099
0.94
0.52
6.1
4.7
6.9
6.9
mmol/l
0.02
471
4803
40
333
1.21
0.51
2.6
2.6
2.1
1.4
g/l
0.33
30
277
95
849
1.13
0.51
4.8
6.2
1.7
1.4
mmol/l
0.88
88
809
19
247
0.77
0.50
1.4
1.8
—
—
—
0
0
7
110
0.63
0.48
1.3
1.5
—
—
—
0
0
297
2815
1.07
0.48
3.4
3.5
149.5
106.4
e6/l
0.37
248
2237
235
2497
0.93
0.47
2.0
2.2
3.6
3.2
mg/l
1.32
188
2098
19
244
0.78
0.47
1.6
1.4
—
—
—
0
0
5
85
0.59
0.45
1.0
1.4
—
—
—
0
0
161
1499
1.09
0.42
2.1
2.4
10.6
11.7
umol/l
1.21
146
1365
68
607
1.13
0.40
1.4
1.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
7
101
0.69
0.39
3.4
4.4
294.7
339.3
umol/l
—
7
88
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
232
2200
1.07
0.38
3.8
2.7
2288.8
8849.7
umol/l
2.25
196
1822
40
345
1.17
0.38
3.0
3.0
4.0
4.3
pmol/l
2.17
34
293
13
98
1.33
0.37
1.2
1.5
—
—
—
0
0
8
112
0.71
0.37
2.1
3.6
—
—
—
0
0
102
938
1.10
0.36
2.0
2.6
4.3
6.5
ug/l
1.16
85
785
86
940
0.91
0.35
3.0
3.3
286.7
273.6
ng/l
0.06
81
861
17
135
1.26
0.35
1.2
1.4
—
—
—
0
0
32
273
1.18
0.35
2.2
1.5
—
—
—
0
0
31
361
0.85
0.34
1.2
1.4
—
41.1
—
0
19
37
321
1.16
0.34
1.3
1.2
44.8
132.0
iu/ml
3.00
14
119
6
46
1.31
0.33
1.7
1.2
—
—
—
0
0
6
46
1.31
0.33
1.7
1.2
—
—
—
0
0
180
1704
1.07
0.32
2.2
1.9
—
—
—
0
0
63
694
0.90
0.31
3.1
3.7
82.0
99.4
ng/l
0.92
57
590
145
1365
1.07
0.31
2.1
2.4
2.2
2.2
g/l
1.03
130
1247
7
54
1.30
0.30
2.7
1.3
—
—
—
0
0
7
54
1.30
0.30
2.7
1.3
—
—
—
0
0
15
120
1.25
0.30
1.6
2.6
51.0
20.2
mg/l
—
5
32
13
102
1.28
0.30
1.8
1.5
—
—
—
0
0
437
4491
0.96
0.29
4.2
3.1
119.2
55.2
u/l
6.14
401
4065
17
206
0.82
0.29
1.9
1.8
—
—
—
0
0
13
103
1.27
0.28
1.8
1.5
—
—
—
0
0
13
103
1.27
0.28
1.8
1.5
—
—
—
0
0
13
103
1.27
0.28
1.8
1.4
—
—
—
0
0
266
2561
1.05
0.28
3.2
3.5
0.8
0.6
e6/l
0.56
219
2009
8
65
1.23
0.27
1.8
1.3
—
—
—
0
0
8
65
1.23
0.27
1.8
1.3
—
—
—
0
0
13
104
1.25
0.26
1.8
1.4
—
—
—
0
0
5
75
0.67
0.26
1.0
1.1
—
—
—
0
0
6
82
0.73
0.24
1.2
1.2
—
230.2
—
0
26
15
124
1.21
0.24
1.4
1.2
—
—
—
0
0
29
256
1.14
0.23
1.4
1.7
—
211.7
—
0
12
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
39
1.28
0.23
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
102.5
—
0
11
0
11
0.00
0.21
0.0
11.0
—
6.5
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
135
1288
1.05
0.21
2.2
2.5
19.9
21.3
%
0.58
117
1092
20
230
0.87
0.21
2.5
2.4
145.3
85.6
ug/min
0.22
14
133
64
596
1.08
0.20
7.4
8.2
0.7
0.7
%
0.21
64
589
0
14
0.00
0.20
0.0
1.3
—
0.5
—
0
9
6
49
1.23
0.20
1.0
1.1
—
—
—
0
0
153
1470
1.05
0.19
3.0
3.2
3.2
2.1
e6/l
0.80
96
857
59
632
0.93
0.19
3.7
3.1
60.5
58.2
ml/min/173m2
0.21
22
288
56
521
1.08
0.19
3.6
2.9
0.4
0.4
e6/l
0.03
56
507
68
638
1.07
0.18
4.8
3.8
5.1
5.2
kpa
0.22
62
584
34
372
0.91
0.17
5.2
3.4
1.5
1.5
mmol/l
0.05
34
365
5
67
0.75
0.17
1.0
1.1
1.2
1.5
nmol/l
—
5
55
5
69
0.72
0.17
1.0
1.1
123.0
114.9
%
—
5
63
12
101
1.19
0.16
1.9
1.4
—
—
—
0
0
156
1507
1.04
0.16
21.4
29.4
1.5
1.5
inr
0.11
21
189
51
544
0.93
0.15
1.6
2.2
9.8
12.1
nmol/l
0.95
41
462
22
197
1.12
0.15
1.4
1.6
0.1
24.6
iu/ml
—
7
49
41
381
1.08
0.15
2.2
1.7
—
—
—
0
0
27
295
0.91
0.14
1.1
1.3
—
—
—
0
0
10
84
1.19
0.14
1.6
1.7
—
—
—
0
0
63
598
1.06
0.13
5.0
3.9
1.4
2.0
mmol/l
0.69
52
445
208
2029
1.03
0.13
2.8
2.7
5.3
4.8
e6/l
0.47
193
1792
150
1543
0.97
0.12
2.6
3.0
2.3
1.2
e6/l
1.32
94
922
32
344
0.93
0.12
1.2
1.2
172.7
165.4
u/ml
0.02
25
314
25
230
1.09
0.11
1.2
1.2
—
—
—
0
0
12
136
0.88
0.11
1.4
1.2
—
—
—
0
0
19
208
0.91
0.10
1.6
2.2
118.2
126.8
g/l
0.56
13
158
63
604
1.05
0.10
1.6
1.6
1.6
1.6
%
0.34
55
494
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
19
207
0.92
0.09
3.4
3.9
41.4
29.6
mg/l
0.45
12
140
123
1198
1.03
0.09
1.9
1.8
—
—
—
0
0
28
299
0.93
0.09
2.2
3.3
0.7
0.9
nmol/l
1.04
16
237
63
655
0.96
0.09
7.4
6.0
24.8
24.5
mmol/l
0.34
63
609
119
1165
1.02
0.07
5.9
6.4
1.2
1.4
mmol/l
0.19
94
881
327
3301
0.99
0.06
3.6
3.5
—
—
—
0
0
637
6337
1.01
0.06
14.3
7.2
124.5
81.6
u/l
9.65
613
5856
24
229
1.05
0.04
1.2
1.2
—
—
—
0
0
169
1671
1.01
0.04
1.8
1.6
2.0
1.4
mg/l
1.27
128
1326
20
208
0.96
0.02
2.0
1.7
11274.3
18235.2
e6/l
0.43
15
144
25
243
1.03
0.01
1.6
1.4
225.8
275.2
ug/g
0.56
17
146
11
114
0.96
0.00
1.6
1.3
—
—
—
0
0
11
114
0.96
0.00
1.3
1.1
—
—
—
0
0
18
176
1.02
0.00
1.7
1.4
—
—
—
0
0
119
1194
1.00
0.00
1.9
1.8
—
—
—
0
0
60
602
1.00
0.00
7.4
8.1
1.3
1.4
%
0.41
60
595
18
181
0.99
0.00
1.8
1.5
—
—
—
0
0
94
942
1.00
0.00
3.3
3.4
2.1
2.1
mmol/l
0.02
65
744
21
207
1.01
0.00
1.7
2.5
16.4
15.6
%
—
5
104
15
145
1.03
0.00
1.1
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
3.0
—
0.6
—
0
8
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
1.3
2.1
—
80.5
—
0
10
5
56
0.89
0.00
4.4
4.1
—
—
—
0
0
5
49
1.02
0.00
1.4
1.7
1.4
3.7
u/field
—
5
31
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
25.6
—
0
5
0
6
0.00
0.00
0.0
5.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
0.00
1.0
1.6
13.8
16.0
umol/l
—
5
48
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
8.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
7
69
1.01
0.00
1.6
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_SECONDARY_WITHOUT_SITESPEC – Malignant neoplasm, without specification of site
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).